BGS 649

Drug Profile

BGS 649

Alternative Names: BGS-649

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Mereo BioPharma; Novartis
  • Class
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypogonadism
  • Discontinued Endometriosis

Most Recent Events

  • 13 Dec 2016 Mereo BioPharma has patent protection for BS-649 in United Kingdom and USA
  • 01 Nov 2016 Mereo BioPharma initiates a phase II extension trial for Hypogonadism in USA (PO, Capsule) (NCT02908074)
  • 16 Sep 2016 Mereo BioPharma plans a phase II extension trial for Hypogonadism in USA and United Kingdom (PO, Capsule) (NCT02908074)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top